Orgaran (Danaparoid Sodium)

Danaparoid Sodium, the active ingredient in Orgaran, is a Heparinoid (Anticoagulant) presented as an unknown/unknown for intravenous use. It is used to prevent and treat venous thromboembolism and to manage heparin‑induced thrombocytopenia in adult patients. GNH USA supplies Orgaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Orgaran is a heparinoid anticoagulant that acts on the coagulation cascade to reduce clot formation. - Deep vein thrombosis: prevents clot propagation and facilitates resolution in at‑risk patients. - Pulmonary embolism: reduces the size of existing emboli and prevents new clot formation in the pulmonary arteries. - Heparin‑induced thrombocytopenia (HIT): provides an alternative anticoagulant option when heparin therapy is contraindicated.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Minor bleeding at injection site: mild bruising or oozing. - Gastrointestinal upset: nausea or abdominal discomfort. - Elevated liver enzymes: transient increase in hepatic transaminases. - Rash or mild skin irritation: localized erythema.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Thrombocytopenia: significant drop in platelet count unrelated to HIT. - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention.

Use Orgaran only under careful clinical supervision and after evaluating individual risk factors. - Renal impairment: monitor renal function and adjust therapy as needed. - Bleeding risk: assess patient history of bleeding disorders before initiation. - History of HIT: contraindicated in patients with prior heparin‑induced thrombocytopenia. - Concurrent anticoagulants: avoid combination with other anticoagulant agents unless specifically directed. - Pregnancy: consider only if potential benefits outweigh risks to the fetus. - Store at ambient temperature: keep in original container, protect from light and moisture.

Co‑administration with certain drugs can alter anticoagulant effect.

Major Interactions (Avoid): - Direct thrombin inhibitors (e.g., dabigatran): may cause uncontrolled bleeding. - High‑dose aspirin or other antiplatelet agents: significantly increase hemorrhagic risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may potentiate bleeding tendency. - Certain antibiotics (e.g., quinolones): can affect platelet function. - Vitamin K antagonists (e.g., warfarin): may require dose adjustments and close INR monitoring.